Betimol

Migraine, Open-angle glaucoma, Migraine Disorders + 6 more
Treatment
20 Active Studies for Betimol

What is Betimol

TimololThe Generic name of this drug
Treatment SummaryTimolol is a medication used to reduce pressure in the eyes and treat high blood pressure. It is available in eye drop and tablet form and was approved by the FDA in 1978. It is produced by several manufacturers and is an effective treatment for conditions like open-angle glaucoma and high blood pressure.
Timopticis the brand name
Betimol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Timoptic
Timolol
1978
167

Effectiveness

How Betimol Affects PatientsWhen taken as eye drops, Timolol quickly lowers the pressure in the eye. It can also be taken as a tablet, and in this form it reduces blood pressure, heart rate, and the body's production of adrenaline. Timolol usually takes effect within 20 minutes of being administered as eye drops, and its effects can last up to 24 hours.
How Betimol works in the bodyTimolol works by blocking certain receptors in the heart, blood vessels, and bronchial muscles. This prevents catecholamines from binding to these receptors, which helps to reduce heart rate and blood pressure. Timolol also decreases reflex orthostatic hypotension. Timolol's effect on reducing ocular pressure is unknown, but it may be due to a decrease in blood supply to the ciliary body or disruption of prostaglandin production.

When to interrupt dosage

The dose of Betimol is contingent upon the diagnosed condition, including Open Angle Glaucoma, requiring supplementary or substitute therapy and Ocular Hypertension. The amount of dosage is dependent on the technique of delivery (e.g. Ophthalmic or Solution, gel forming/drops) denoted in the table beneath.
Condition
Dosage
Administration
Migraine
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Migraine Disorders
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
insufficient response to beta-blockers
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
requiring adjunctive or replacement therapy
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Open-angle glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
inadequate response to other therapeutic measures
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Open Angle Glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Ocular Hypertension
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic

Warnings

Betimol has seven contraindications and should be avoided in the presence of the following conditions in the table below.Betimol Contraindications
Condition
Risk Level
Notes
Lung Diseases, Obstructive
Do Not Combine
Sinus Bradycardia
Do Not Combine
Shock, Cardiogenic
Do Not Combine
Atrioventricular Block
Do Not Combine
Asthma
Do Not Combine
Heart Failure
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Timolol may interact with Pulse Frequency
There are 20 known major drug interactions with Betimol.
Common Betimol Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Timolol.
4-Methoxyamphetamine
Major
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Timolol.
Abediterol
Major
Timolol may decrease the bronchodilatory activities of Abediterol.
Adrafinil
Major
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Timolol.
Agrostis gigantea pollen
Major
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Timolol.
Betimol Toxicity & Overdose RiskThe lowest toxic dose of timolol maleate for rats is 1028mg/kg, and for mice it is 1137mg/kg. Overdosing on timolol can cause dizziness, headache, difficulty breathing, a slow heart rate, and asthma-like symptoms. In severe cases, it can lead to cardiac arrest. Dialysis can be used to treat the overdose, but it may not be as effective for those with kidney problems.
image of a doctor in a lab doing drug, clinical research

Betimol Novel Uses: Which Conditions Have a Clinical Trial Featuring Betimol?

172 active studies are examining the potential of Betimol to provide an adequate response in cases of insufficient response to beta-blockers, Insufficient response to other therapies and necessitating adjunct or substitution therapy.
Condition
Clinical Trials
Trial Phases
Open-angle glaucoma
45 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 4, Early Phase 1, Phase 1
Open Angle Glaucoma
10 Actively Recruiting
Phase 3, Not Applicable, Phase 4
Ocular Hypertension
10 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable, Phase 4
requiring adjunctive or replacement therapy
0 Actively Recruiting
inadequate response to other therapeutic measures
0 Actively Recruiting
Migraine Disorders
1 Actively Recruiting
Phase 3
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Glaucoma
0 Actively Recruiting
insufficient response to beta-blockers
0 Actively Recruiting

Betimol Reviews: What are patients saying about Betimol?

4Patient Review
11/22/2008
Betimol for Increased Pressure in the Eye
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about betimol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Betimol used for?

"This medication decreases fluid in the eye to help treat glaucoma and other eye diseases."

Answered by AI

Is Betimol the same as timolol?

"The active drug ingredient in Timoptic, Istalol, and Betimol is timolol. However, Timoptic and Istalol both contain timolol maleate while Betimol contains timolol hemihydrate."

Answered by AI

Does Betimol cause hair loss?

"This has been reported as a side effect of the use of timolol, betaxolol, and levobunolol. Hair loss starts from 1 to 24 months after starting the treatment, but the hair growth normally returns to normal after 4 to 8 months of stopping the beta-blocker."

Answered by AI

What is the generic name for Betimol?

"Timolol is a beta-blocker that also reduces pressure inside the eye. Betimol is used to treat open-angle glaucoma and other causes of high pressure inside the eye."

Answered by AI

Clinical Trials for Betimol

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Have you considered Betimol clinical trials? We made a collection of clinical trials featuring Betimol, we think they might fit your search criteria.Go to Trials
Have you considered Betimol clinical trials? We made a collection of clinical trials featuring Betimol, we think they might fit your search criteria.Go to Trials
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Have you considered Betimol clinical trials? We made a collection of clinical trials featuring Betimol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security